Ameluz, Gleolan, Levulan, Gliolan (aminolevulinic acid) is a small molecule pharmaceutical. Aminolevulinic acid was first approved as Ameluz on 1999-12-03. It is used to treat actinic keratosis in the USA. It has been approved in Europe to treat actinic keratosis, basal cell carcinoma, and glioma. Levulan kerastick's patent is valid until 2038-01-12 (FDA).
|Trade Name||Ameluz, Gliolan|
|Common Name||Aminolevulinic acid|
|Indication||actinic keratosis, basal cell carcinoma, glioma|